Fig. 1 · Structure

Documents & Downloads

Gossypol

Cat. No. A10435 CAS 303-45-7

dehydrogenase inhibitor

Gossypol is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes.

In Stock

Publications for Gossypol

2 publications citing this product

  1. Amy L. Farthing, .et al. , Wildlife Society Bulletin, 2018, 42(3):460-466
  2. Jin Qu, .et al. , Biomed Res, 2017, 28 (8): 3355-3361

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Gossypol requires model-specific interpretation as a putative BH3 mimetic. In a functional panel of murine leukemia models, it showed no direct mitochondrial activity up to 10 µM during 1 h of BH3 profiling, although intact-cell killing occurred after 24 h, including some killing of BAX/BAK-deficient cells. These results limit attribution of cell death to potent, direct mitochondrial BCL-2-family inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Bcl-xL Ki 0.5-0.6 μM
Bcl-2 Ki 0.2-0.3 mM

In Vitro Studies

In HUVECs on Matrigel, reported racemic gossypol disrupted tube-like structures at 30 µM after 12 h relative to untreated and DMSO controls. The microscopy result does not distinguish tube inhibition from cell damage and does not establish tumor selectivity. [2]

Functional BH3 profiling and paired cell-death testing

Cell-based study · Murine leukemia model lines dependent on human BCL-2, BCL-XL, MCL-1 or BFL-1, plus BAX/BAK double-knockout control cells; permeabilized-cell mitochondrial and intact-cell assays. [1]

Gossypol showed no mitochondrial activity at concentrations up to 10 µM in this functional profiling system, despite intact-cell killing after 24 h. The authors also observed some killing of BAX/BAK double-knockout cells. These findings limit its use as a potent direct BH3 mimetic in these models; they do not measure purified-protein binding or establish the absence of all indirect BCL-2-family effects.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Direct mitochondrial cytochrome c release after 1 hFunctional mitochondrial response No mitochondrial activity at concentrations up to 10 µM[1]
Intact-cell death after 24 hAnnexin V positivity Cell killing occurred, including a lesser degree of killing in BAX/BAK double-knockout cells; no exact percentage or IC50 extracted.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Mitochondrial activity assessed up to 10 µM, as stated in Discussion; intact-cell concentration series shown in Figure 2A, without extracting exact individual doses from the log plot.
Exposure duration
1 h for iBH3 mitochondrial response; 24 h for intact-cell death
Method
Direct exposure of digitonin-permeabilized cells for mitochondrial profiling; separate intact-cell compound exposure for viability testing.
Vehicle
DMSO stock solvent; final DMSO percentage not stated in the read assay methods.
Co-treatment
Gossypol alone; other compounds were comparator treatments, not combinations.
Reported limits
Gossypol catalog number, enantiomer ratio and lot identity are not specified in Compounds. Exact individual concentration steps are not enumerated in the read text.
Methods and source locations

Compound reported in the paper: Gossypol; Compound label in the paper: Sigma-Aldrich gossypol; stereochemistry not specified

Applies to the reported Sigma-Aldrich gossypol and the specified functional assays; it does not validate an Adooq lot or establish universal target selectivity.

Figure 2A and caption; Figure 1B validation; Materials and methods: Compounds, iBH3 profiling, Viability testing, Data reduction; Results gossypol paragraph; Discussion

Direct mitochondrial cytochrome c release after 1 h: iBH3 flow cytometry in permeabilized cells; Figure 2 caption specifies N ≥ 6 and SD bars. Buffer-only and no-antibody controls define signal range; BH3 peptide responses and alamethicin validate the model panel. — Figure 2A and caption; Figure 1B validation; Materials and methods: Compounds, iBH3 profiling, Viability testing, Data reduction; Results gossypol paragraph; Discussion

Intact-cell death after 24 h: Annexin V/Hoechst flow cytometry; Figure 2 caption specifies N ≥ 3 and SD bars. Paired mechanistic comparison with iBH3; no curve-derived decimals. — Figure 2A right panel and caption; Results gossypol paragraph; Viability testing

Racemic gossypol alters HUVEC tube-like structures

Cell-based study · Human umbilical vein endothelial cells (HUVECs) on Matrigel; untreated and DMSO solvent controls and separate suramin comparator. [2]

Representative images showed disrupted tube-like structures at the highest tested gossypol concentration (30 µM) after 12 h. This is a qualitative endothelial phenotype. The experiment did not separate inhibition of tube formation from cell damage, and it does not demonstrate tumor-selective angiogenesis inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Formation of endothelial tube-like networksQualitative microscopy Tube-like structures were disrupted at 30 µM; no quantitative tube length, branch-count reduction or IC50 adopted.[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.5, 2.5, 5, 10, 20 and 30 µM
Exposure duration
12 h
Method
HUVECs on Matrigel following serum starvation; microscopy of tube-like structures.
Vehicle
DMSO solvent control shown in Figure 2B1; final DMSO percentage not specified in the read tube-assay methods.
Co-treatment
Gossypol alone; suramin is a separate comparator.
Reported limits
No numerical tube-network analysis or viability-matched tube comparison is supplied in the adopted figure/results. The tube-assay methods do not specify final vehicle concentration.
Methods and source locations

Compound reported in the paper: (±)-Gossypol; Compound label in the paper: Sigma-Aldrich racemic gossypol

Reported racemic material and HUVEC morphology only; no Adooq lot validation, dose conversion, mammalian antitumor efficacy or clinical inference.

Materials and methods: Materials, Cell culture, Tube formation assay; Results: Inhibitor effect of (±)-gossypol on HUVEC tube formation; Figure 2 A1-H2 and caption; Discussion

Formation of endothelial tube-like networks: Matrigel tube assay; cells serum-starved for 4 h in EBM-2 with 1% FBS; structures photographed after 12 h. Figure 2 caption describes representative independent triplicate assays. — Materials and methods: Materials, Cell culture, Tube formation assay; Results: Inhibitor effect of (±)-gossypol on HUVEC tube formation; Figure 2 A1-H2 and caption; Discussion

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 303-45-7
Applications dehydrogenase inhibitor
Formula C30H30O8
Molecular Weight 518.6
SMILES
CC1=C(C(=C2C(=C1)C(=C(C(=C2C=O)O)O)C(C)C)O)C3=C(C=C4C(=C3O)C(=C(C(=C4C(C)C)O)O)C=O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 95 mg/mL (183.2 mM)
Water Insoluble
Ethanol 8 mg/mL (15.42 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Mariana Villalobos-Ortiz, Jeremy Ryan, Thelma N. Mashaka, et al. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics Cell Death & Differentiation (2020). PMID: 31332296 DOI: 10.1038/s41418-019-0391-9 Source material
  2. [2] Gönül Ulus, A. Tansu Koparal, Kemal Baysal, et al. The anti-angiogenic potential of (±) gossypol in comparison to suramin Cytotechnology (2018). PMID: 30123923 DOI: 10.1007/s10616-018-0247-z Source material

Publications

2 publications citing this product

  1. Amy L. Farthing, .et al. , Wildlife Society Bulletin, 2018, 42(3):460-466
  2. Jin Qu, .et al. , Biomed Res, 2017, 28 (8): 3355-3361

Added to your cart

View Cart Checkout
Loading...